{"id":10199,"date":"2012-04-22T11:46:58","date_gmt":"2012-04-22T11:46:58","guid":{"rendered":"http:\/\/cardiophile.org\/?p=7092"},"modified":"2012-04-22T11:46:58","modified_gmt":"2012-04-22T11:46:58","slug":"newer-antithrombotics-in-atrial-fibrillation-2","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/","title":{"rendered":"Newer antithrombotics in atrial fibrillation"},"content":{"rendered":"<h2><span style=\"color: #008000;\">Newer antithrombotics in atrial fibrillation<\/span><\/h2>\n<p>Why do we need newer antithrombotics in atrial fibrillation? It is well known that long term anticoagulation reduces the incidence of stroke in nonvalvular atrial fibrillation. Vitamin K antagonists like warfarin are highly effective for long term anticoagulation and stroke prevention. But they have numerous limitations including erratic control and drug interactions which are challenging for physicians and patients. Hence the search for newer antithrombotics for stroke prevention in atrial fibrillation.<br \/>\nNewer antithrombotics in atrial fibrillation include the direct thrombin inhibitor dabigatran, direct factor Xa inhibitors like rivaroxaban, apixaban and edoxaban as well as the vitamin K analogue tecarfarin. Otamixaban is a potential intravenous alternative for the acute care setting. In general, direct thrombin and factor Xa inhibitors are small, synthetic molecules with Predictable pharmacokinetics and pharmacodynamic effect, having few drug interactions and do not require routine therapeutic drug monitoring.<\/p>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Newer antithrombotics in atrial fibrillation: DTI -dabigatran, direct factor Xa inhibitors &#8211; rivaroxaban, apixaban, edoxaban; vitamin K analogue tecarfarin.<\/p>\n","protected":false},"author":1,"featured_media":35941,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-10199","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Newer antithrombotics in atrial fibrillation - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"description\" content=\"Newer antithrombotics in atrial fibrillation: DTI -dabigatran, direct factor Xa inhibitors - rivaroxaban, apixaban, edoxaban; vitamin K analogue tecarfarin.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Newer antithrombotics in atrial fibrillation - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"Newer antithrombotics in atrial fibrillation: DTI -dabigatran, direct factor Xa inhibitors - rivaroxaban, apixaban, edoxaban; vitamin K analogue tecarfarin.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2012-04-22T11:46:58+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/newer-antithrombotics-in-atrial-fibrillation-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/newer-antithrombotics-in-atrial-fibrillation-2\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Newer antithrombotics in atrial fibrillation\",\"datePublished\":\"2012-04-22T11:46:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/newer-antithrombotics-in-atrial-fibrillation-2\\\/\"},\"wordCount\":150,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/newer-antithrombotics-in-atrial-fibrillation-2\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/newer-antithrombotics-in-atrial-fibrillation-2\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/newer-antithrombotics-in-atrial-fibrillation-2\\\/\",\"name\":\"Newer antithrombotics in atrial fibrillation - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/newer-antithrombotics-in-atrial-fibrillation-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/newer-antithrombotics-in-atrial-fibrillation-2\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2012-04-22T11:46:58+00:00\",\"description\":\"Newer antithrombotics in atrial fibrillation: DTI -dabigatran, direct factor Xa inhibitors - rivaroxaban, apixaban, edoxaban; vitamin K analogue tecarfarin.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/newer-antithrombotics-in-atrial-fibrillation-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/newer-antithrombotics-in-atrial-fibrillation-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/newer-antithrombotics-in-atrial-fibrillation-2\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/newer-antithrombotics-in-atrial-fibrillation-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Newer antithrombotics in atrial fibrillation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Newer antithrombotics in atrial fibrillation - All About Cardiovascular System and Disorders","description":"Newer antithrombotics in atrial fibrillation: DTI -dabigatran, direct factor Xa inhibitors - rivaroxaban, apixaban, edoxaban; vitamin K analogue tecarfarin.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/","og_locale":"en_US","og_type":"article","og_title":"Newer antithrombotics in atrial fibrillation - All About Cardiovascular System and Disorders","og_description":"Newer antithrombotics in atrial fibrillation: DTI -dabigatran, direct factor Xa inhibitors - rivaroxaban, apixaban, edoxaban; vitamin K analogue tecarfarin.","og_url":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2012-04-22T11:46:58+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Newer antithrombotics in atrial fibrillation","datePublished":"2012-04-22T11:46:58+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/"},"wordCount":150,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/","url":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/","name":"Newer antithrombotics in atrial fibrillation - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/#primaryimage"},"thumbnailUrl":"","datePublished":"2012-04-22T11:46:58+00:00","description":"Newer antithrombotics in atrial fibrillation: DTI -dabigatran, direct factor Xa inhibitors - rivaroxaban, apixaban, edoxaban; vitamin K analogue tecarfarin.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/newer-antithrombotics-in-atrial-fibrillation-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Newer antithrombotics in atrial fibrillation"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/10199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=10199"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/10199\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=10199"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=10199"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=10199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}